Altimmune to Join Influential Healthcare Conference
Altimmune, Inc. (Nasdaq: ALT), a prominent player in the biopharmaceutical industry, is gearing up to showcase its innovative work in peptide-based therapeutics directed at liver and cardiometabolic conditions. The company has confirmed that its management team will be participating in a significant event, the Piper Sandler 37th Annual Healthcare Conference, to discuss their strategic insights and advancements in clinical development.
Conference Highlights
Scheduled for December 3, 2025, at 2:30 p.m. ET, this meeting promises to offer attendees a closer look at the forefront of metabolic disease treatments. The conference format will include a fireside chat, providing a unique platform for Altimmune’s leaders to share their vision and progress directly with an audience of investors and healthcare professionals.
Understanding Altimmune's Innovative Therapies
Altimmune stands out in the biopharmaceutical field with its focus on developing groundbreaking peptide-based treatments. Their leading product candidate, pemvidutide, acts as a dual receptor agonist targeting glucagon and GLP-1 for various conditions, such as metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and related liver diseases. This innovative approach positions Altimmune at the intersection of medicine and technology, striving to offer new hope to patients facing serious health challenges.
About the Conference
As a vital networking opportunity, the Piper Sandler Healthcare Conference attracts numerous industry stakeholders, enabling fruitful dialogue and collaboration. Attendees can expect crucial insights into upcoming trends and innovations in healthcare, along with discussions on current market conditions and investment prospects in biopharmaceuticals.
Company Background
Founded on the principles of innovation and patient care, Altimmune has steadily developed its portfolio of products aimed at addressing significant health issues. The company is committed to advancing its research and clinical programs, fostering a culture of excellence and scientific rigor. By focusing on the unique treatment mechanisms of metabolic diseases, Altimmune continues to lead in its field, seeking to improve patient outcomes and enhance lives.
Community Engagement
In addition to its research endeavors, Altimmune actively engages with its community. The company recognizes the importance of dialogue not just within professional circles but also with the public. By encouraging discussions through their platforms, including social media, Altimmune aims to raise awareness about the critical issues surrounding liver and cardiometabolic diseases.
Frequently Asked Questions
What is the date and time of Altimmune's participation in the conference?
Altimmune will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 2:30 p.m. ET.
What is pemvidutide, and what conditions does it target?
Pemvidutide is Altimmune's lead product candidate, designed as a glucagon/GLP-1 dual receptor agonist aimed at treating metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Where can I watch the conference session?
The session will be available via webcast, accessible through the Events section of Altimmune's website.
How can I follow Altimmune's developments?
Altimmune encourages its followers to stay connected through social media platforms such as LinkedIn and X for updates and news regarding their innovative therapies.
Who should be contacted for investor inquiries?
Lee Roth from Burns McClellan is available for investor contacts at the provided phone number 646-382-3403, or via email.
